Drug Target Review
JUNE 9, 2025
To do this, Alltrna leverages the unique biology of tRNA and its AI-enabled platform to design engineered tRNAs that can restore full-length protein production in diseases caused by shared genetic mutations, such as premature termination codons. Alltrna focuses on a mutation-driven approach.
Drug Target Review
JULY 5, 2023
After binding, the transposase enzyme will excise the flanked section of DNA (termed the transposon) and insert it into sites in the genome at specific target sequences. An example of the former includes a report in the journal Nature of a new tool that can increase the amount of DNA that can be inserted using CRISPR-Cas9 technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog: Biosimilars
MARCH 5, 2024
Gaulkin & Riëtte van Laack — As readers of this blog know, there is a lot of contention about the naming of alternative protein products (APPs), including both plant-based and cell-cultured alternatives for (traditional) animal products. By Sophia R.
Broad Institute
AUGUST 24, 2022
Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors. "The These data suggest a multi-omics predictor for chemotherapy response is within reach.
Sygnature Discovery
SEPTEMBER 12, 2024
Structures solved of many different protein classes, including membrane proteins, protein complexes and recently RNA. With capabilities across X-ray Crystallography Crystallisation/co-crystallisation screening of proteins, DNA, and RNA using in-house and commercial screens at various temperature.
Dark Matter Blog
JULY 16, 2021
As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. 49 years ago, when I was 16 years old, I wanted to do exactly what I am doing now. The only subject in school that held my interest was biology.
Broad Institute
JANUARY 14, 2025
The treatment, which uses base editing to make a single-letter change in DNA, reduced levels of the disease-causing prion protein in the brain by as much as 60 percent. In 2018, Liu, who works on the same floor as Minikel and Vallabh at Broad, approached them and proposed a collaboration.
Expert insights. Personalized for you.
80 
Let's personalize your content